Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Eisai

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lenvatinib Mesylate,Pembrolizumab

            Therapeutic Area: Oncology Product Name: Lenvima

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 15, 2021

            Details:

            The pivotal Phase 3 Study 309/KEYNOTE-775 evaluated LENVIMA in combination with KEYTRUDA® in patients with advanced endometrial cancer, following at least one prior platinum-based regimen in Japan, the United States, Europe and other countries.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lecanemab

            Therapeutic Area: Neurology Product Name: BAN2401

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Biogen

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 05, 2021

            Details:

            Lecanemab is an investigational humanized monoclonal antibody that binds to neutralize and eliminate soluble, toxic amyloid beta aggregates that are thought to contribute to the neurodegenerative process in AD.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lemborexant

            Therapeutic Area: Sleep Product Name: Dayvigo

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2021

            Details:

            DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): E7090

            Therapeutic Area: Oncology Product Name: E7090

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 22, 2021

            Details:

            In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eslicarbazepine Acetate

            Therapeutic Area: Neurology Product Name: Zebinix

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Bial

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination February 17, 2021

            Details:

            BIAL takes the lead for the marketing and distribution of Zebinix® (eslicarbazepine acetate) in Europe. Eslicarbazepine acetate is a once-daily anti-epileptic used to treat epilepsy patients with focal seizures (partial-onset seizures).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lenvatinib,Pembrolizumab

            Therapeutic Area: Oncology Product Name: Lenvima

            Highest Development Status: Phase III Product Type: Small molecule

            Recipient: Merck & Co. Inc.

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 13, 2021

            Details:

            KEYTRUDA Plus LENVIMA significantly reduced risk of disease progression or death by 61% versus sunitinib, with a median PFS of nearly two years versus nine months for sunitinib.